Can-Fite BioPharma (CANF) Cash & Equivalents (2013 - 2026)
Can-Fite BioPharma (CANF) recorded Cash & Equivalents of $2.99 million in Q2 2026, down 53.7% from $6.45 million a year earlier.
Powered by 
Analysis
Can-Fite BioPharma (CANF) Cash & Equivalents (2013 - 2026) Analysis & Trends
At the end of FY2025, Can-Fite BioPharma reported Cash & Equivalents of $5.53 million, up 14.6% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of -7.7% (FY2020 to FY2025).
- Across earlier years, Cash & Equivalents came in at $4.83 million in FY2024 (+12.8%), $4.28 million in FY2023 (-2.6%), $4.39 million in FY2022 (-46.9%) and $8.27 million in FY2021 (unchanged).
- The Q2 2026 figure is the lowest quarterly Cash & Equivalents since Q4 2023.
- On a year-over-year basis, Cash & Equivalents rose in three of the last four quarters, with growth averaging 14.9%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 206.6% in Q4 2021, against a decline of 77.3% in Q2 2022 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Can-Fite BioPharma | 1.84 Mn | -17.86 Mn | - | 2.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.99 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Jun 30, 2025 | 6.45 Mn |
| Dec 31, 2024 | 4.83 Mn |
| Jun 30, 2024 | 4.72 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Sep 30, 2023 | 3.38 Mn |
| Jun 30, 2023 | 3.46 Mn |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 4.39 Mn |
| Sep 30, 2022 | 3.73 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 5.50 Mn |
| Dec 31, 2021 | 8.27 Mn |
| Sep 30, 2021 | 5.81 Mn |
| Jun 30, 2021 | 7.54 Mn |
| Mar 31, 2021 | 2.74 Mn |
| Dec 31, 2020 | 2.70 Mn |
| Sep 30, 2020 | 10.22 Mn |
| Jun 30, 2020 | 9.06 Mn |
API Access
Can-Fite BioPharma Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=CANF&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "CANF", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=CANF&period=max&api_key=YOUR_API_KEY");
const data = await res.json();